Compare ICL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICL | AXSM |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.5B |
| IPO Year | 2001 | 2015 |
| Metric | ICL | AXSM |
|---|---|---|
| Price | $4.14 | $135.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 22 |
| Target Price | $5.74 | ★ $264.62 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 11-10-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.83 | $49.25 |
| Revenue Next Year | $3.48 | $52.08 |
| P/E Ratio | $31.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $123.00 |
| 52 Week High | $6.97 | $260.19 |
| Indicator | ICL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 25.23 | 36.23 |
| Support Level | N/A | $123.00 |
| Resistance Level | $5.79 | $151.31 |
| Average True Range (ATR) | 0.12 | 6.95 |
| MACD | -0.03 | 1.34 |
| Stochastic Oscillator | 4.58 | 41.86 |
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates revenue from Brazil, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.